Sandu Pharmaceuticals (524703) Q1 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, were approved, with statutory auditors issuing an unmodified limited review report.

• Directors' Report, Management Discussion and Analysis, and Corporate Governance Report for the year ended March 31, 2024, were approved.

• Dividend of ₹0.80 per equity share (8% of face value ₹10) recommended for FY24, subject to shareholder approval at the 39th AGM.

• 39th AGM scheduled for September 30, 2024, via video conferencing.

Financial highlights

• Standalone revenue for Q1 FY25 was ₹1,704.54 lakhs, down from ₹1,765.71 lakhs in Q1 FY24 and up from ₹1,559.77 lakhs in Q4 FY24.

• Standalone net profit for Q1 FY25 was ₹16.69 lakhs, up from ₹10.97 lakhs in Q1 FY24 but down from ₹59.24 lakhs in Q4 FY24.

• Consolidated revenue for Q1 FY25 was ₹1,704.54 lakhs, compared to ₹1,765.71 lakhs in Q1 FY24 and ₹1,559.77 lakhs in Q4 FY24.

• Consolidated net profit for Q1 FY25 was ₹16.69 lakhs, up from ₹10.93 lakhs in Q1 FY24 and down from ₹59.46 lakhs in Q4 FY24.

• Basic and diluted EPS for Q1 FY25 stood at ₹0.17 (standalone and consolidated).

Outlook and guidance

• The company continues to focus on its core Ayurvedic property medicines segment.

• No specific forward-looking financial guidance was provided.